• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
CC-671

CC-671

Product ID C086007
Cas No. 1618658-88-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $129.60 In stock
5 mg $306.70 In stock
25 mg $715.60 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.

Product Info

Cas No.

1618658-88-0

Purity

≥98%

Formula

C28H28N6O4

Formula Wt.

512.57

IUPAC Name

4-{[4-(Cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide

Synonym

CC 671, CC671

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

C086007 MSDS PDF

Info Sheet

C086007 Info Sheet PDF

References

Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.

Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • Z324098

    Ziconotide

    Non-opioid analgesic.

    ≥95%
  • T3100

    Thyrotropin-releasing Hormone

    Endogenous tripeptide, involved in HPA signalin...

    ≥95%
  • P2510

    4-Phenylbutylisothiocyanate

    Synthetic ITC.

    ≥98%
  • P7056

    Procaterol Hydrochloride

    β2-adrenergic agonist.

    ≥98%
  • M3577

    Mitiglinide Calcium

    ATP-sensitive K+ channel blocker, potential RyR...

    ≥98%
  • I5203

    Inauhzin

    p53 activator, IMPDH and SIRT1 inhibitor.

    ≥98%
  • S520011

    SN-011

    STING antagonist

    ≥97%
  • G4400

    Glabridin

    Isoflavonoid found in Glycyrrhiza; GABA-A posit...

    ≥98%
  • L5993

    Loxoprofen Sodium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • G8225

    Guggulsterone

    Steroid found in myrrh; FXR antagonist.

    ≥98%
  • L8010

    D-Luciferin Potassium

    Heterocyclic light-emitting compound, natural l...

    ≥98%
  • H0142

    Haloperidol

    Butyrophenone; σ2 agonist, α1-adrenergic, D2,...

    ≥95%
  • A9600

    AZD-3463

    ALK and IGF-1R inhibitor.

    ≥99%
  • G1310

    GDC-0349

    mTOR inhibitor.

    ≥98%
  • O7218

    Oseltamivir Phosphate

    Viral neuraminidase inhibitor, potential MAO-A ...

    ≥98%
  • A480010

    AM630

    CB2 receptor antagonist.

    ≥97%
  • A6818

    Arenobufagin

    Bufanolide steroid found in Bufo arenarum;VEGFR...

    ≥98%
  • C9615

    Cyclosporin B

    Cyclic peptide; calcineurin inhibitor.

    ≥95%
  • I7468

    Isradipine

    Calcium channel blocker.

    ≥98%
  • B5728

    Bohemine

    Purine derivative; CDK inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only